CAR-T Cell Immunotherapy (idecabagene vicleucel) for multiple myeloma
-
Last Update: 2020-06-22
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Bristol Myers Squibb and Bluebird Bio reported Tuesday (March 31, 2020) that they have filed a listing application with the FDA for ide-cel to treat relapsed refractory multiple myeloma, who have received at least three treatments, including immunomodulators, protease inhibitors, and anti-CD38 antibodiesidecabagene vicleucel (ide-cel) is a CAR-T cell immunotherapy that targets BCMATNFRSF17 is a member of the TNF receptor family, known as tumor necrosis factor receptor super family member 17, also known as B-cell maturation antigen (BCMA) or CD269, a protein encoded by the TNFRSF17 geneThe receptor is expressed on the surface of B lymphocytes and plasma cells and is a marker protein for b lymphocyte maturationThe Phase II KarMMa trial recruited 140 adult patients who had received at least three previous treatments, of whom 128 received ide-cel treatmentThe main data reported in the 12-month report showthat the study reached the primary endpoint of the overall mitigation rate (ORR) and the secondary endpoint of the total mitigation rate (CR)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
